0337 24-Month Patterns of Sleep Medication Use with a Prescription Digital Therapeutic for Chronic Insomnia – A Retrospective Analysis

Abstract Introduction Cognitive-behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, but sedative-hypnotic medications are often used first, despite contraindications and risk of misuse. This study assessed change in sedative/hypnotic use/dosage patients with chronic treated Somryst® (tested as SHUTi), a prescription digital therapeutic (PDT) delivering CBT-I. Methods A retrospective claims data analysis was conducted use prescribed sedatives/hypnotics (days’ supply: 8-200; units dispensed: >12) self-identified sleep problems who initiated PDT (index) between June 2016 December 2018, had available closed 24 months pre- post-index. Eligible were at least once year prior to initiation PDT, or 90 days after initiation. Outcomes evaluated: dose change, stoppage/initiation, medication switch, using nearest pre-index furthest post-index medication. Dose evaluated total strength per day: quantity dispensed/day's supply. Medication switch cessation medication, accompanied by different sedative/hypnotic. Results Of 248 individuals observed, 131 (52.8%) utilized an eligible On average, on 1.5 (median 2, range 1-6) medications. In 59 (45% cohort), there either decrease dosage (13 patients, 9.9%), full stopping (52 39.7%), all (41 31.3%). 32 (24% increase (8 6.1%) new (28 21.3%). Twenty-two (16.7%) switched period. Forty-three (32%) experienced no changes specific its dosage, including 25 (19%) another already counted groups described above, 18 (13.7%) not elsewhere. Conclusion Real-world evidence from CBT-I demonstrated reduction and/or stoppage almost half population, third such Support (if any) funded Pear Therapeutics (US), Inc.